Group Performance

• Revenue: US$959.5 million, +61.4% year-on-year
• Gross profit: US$553.2 million, +103.3% year-on-year
• Adjusted net profit: US$230.3 million, +285.0% year-on-year

Business Units’ Performance

• GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year
• ProBio: US$388.7 million, +309.1% year-on-year
• Bestzyme: US$58.0 million, +7.9% year-on-year

PISCATAWAY, N.J., March 16, 2026 /PRNewswire/ —

GenScript Biotech Corporation continues to scale platform synergies, global reach, and automation-enabled operations, with revenue reaching US$959.5 million (+61.4% YoY); adjusted net profit rising up to US$230.3 million.

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology innovation, today announced financial results for full year 2025.

“2025 was a year of accelerated growth and disciplined execution for GenScript,” said Sherry Shao, Rotating CEO of GenScript Biotech Corporation. “We delivered strong results while continuing to strengthen the integrated capabilities that differentiate GenScript – from gene synthesis and protein engineering to biologics development and industrial biotechnology innovation. Our performance reflects both solid end-market demand and the benefits of a more connected, globally-scaled operating model.”

“Looking ahead, GenScript is well positioned to benefit from the next wave of biotechnology innovation, including AI-enabled discovery, advanced therapeutics, and rising demand for globally-reliable research and manufacturing infrastructure. We remain focused on high-quality growth, operational discipline, and long-term value creation for customers and shareholders.”

FY2025 Financial Highlights*

Revenue

In 2025, GenScript recorded revenue of approximately US$959.5 million, representing an increase of 61.4% from approximately US$594.5 million in 2024. The growth is primarily attributable to (i) substantial increase of license revenue, mainly derived from LaNova sublicensing, (ii) continuous investment in commercial efforts, combined with global brand transformation, and enhanced brand awareness, particularly in Europe and North America, (iii) growing industry demand for AI-driven drug development, and multi-antibody drug development, fueling growth in gene-to-protein businesses, (iv) harnessing rebound in biologics CDMO demand and capitalizing on recovering market conditions, (v) continuous market expansion supported by launch of innovative industrial enzyme products.

Gross Profit

Group’s gross profit increased by 103.3% to approximately US$553.2 million from approximately US$272.1 million in 2024 – primarily attributable to revenue expansion, especially license revenue, in biologics development services. Adjusted gross profit increased by 98.6% over the prior period.

Selling and Distribution Expenses

Selling and distribution expenses increased by 12.9% to approximately US$99.5 million, from approximately US$88.1 million in 2024 – attributable to the (i) expansion of commercial teams and local recruitment of experienced professionals, (ii) continued investment in regional operations, supporting business development and customer engagement in key global markets. Adjusted selling and distribution expenses increased by 14.6% over the prior period.

Administrative Expenses

Administrative expenses increased by 12.4% to approximately US$128.6 million in 2025 from approximately US$114.4 million in 2024 – mainly attributable to (i) continued expenditures in capacity expansion infrastructure and enhanced administrative functions (ii) initial phase expenses for the new site. Adjusted administrative expenses increased by 14.8% over the prior period.

R&D Expenses

R&D expenses increased by 32.4% to approximately US$71.2 million from approximately US$53.8 million in 2024 – mainly attributable to the accelerated recruitment of highly-skilled professionals and expansion of strategic research initiatives. Adjusted R&D expenses increased by 32.8% over the prior period.

Adjusted Net Profit

Adjusted net profit of the Group was approximately US$230.3 million for FY2025.

Strategic Drivers of FY2025 Performance

1. Integrated platform synergies
The Group continued to capture greater value from integration across its technology platforms. LSG’s gene-to-protein workflow became an increasingly important growth engine, with platform synergies contributing approximately 65% of LSG’s 2025 revenue growth.

2. Global reach and diversified revenue base
GenScript further strengthened its international footprint, growing across NA, EU, and APAC. Europe delivered five consecutive years of growth, with 2025 revenue increasing 29% year-on-year, while Asia-Pacific grew 33% year-on-year, underscoring broader geographic diversification.

3. Product and technology innovation
GenScript continued to advance proprietary technologies and product platforms spanning life science research tools, biologics discovery and development, and industrial biotechnology applications. These innovations strengthened differentiation, improved productivity, and supported customer adoption across high-growth applications.

4. Automation and digitalization
Expanded use of automation and AI-enabled systems in R&D and manufacturing, improved efficiency, shortened timelines, and enhanced operational resilience. Within 2025, four major production sites of LSG are upgraded into automated, AI-driven “lights-out” facilities, and 60% of global production capacity will be powered by AI-driven automation by end-2026.

Business Segment Highlights

GenScript Life Science Group
GenScript LSG generated US$522.1 million in revenue, up 14.8% year-on-year, surpassing the US$500 million milestone. The business continued to benefit from adoption of its integrated gene-to-protein platform, strong demand from pharma and biotech customers, and growing traction in AI-enabled discovery.

Among key highlights:

• Revenue from integrated protein expression services grew +50%.
• Orders flowing from gene synthesis into integrated protein expression platform increased +160% year-on-year.
• Serving 66,000+ active customers globally and cited in 118,000+ publications, reinforcing its position as a trusted, global scientific community partner.

ProBio
ProBio delivered exceptional growth in 2025, with revenue reaching US$388.7 million, up 309.1% year-on-year. Excluding one-time items, fee-for-service revenue grew 21% year-on-year, with improving order momentum. ProBio secured 41 antibody & protein drug development projects; 60 cell and gene therapy CDMO projects and 20 new IND clearances across CGT programs.

Expanding its discovery, CMC, and GMP manufacturing capabilities, ProBio strengthened its position with international customers and advanced flexible collaboration models – including fee-for-service, co-development, and out-licensing.

Bestzyme
Bestzyme generated US$58.0 million revenue, up 7.9% year-on-year. The business continued advancing industrial biotechnology innovation through new enzyme products, stronger AI-enabled R&D capabilities, and international market development.

Performance highlights include increased contribution from innovative enzyme products, progress in sweet protein commercialization, and 140% improvement in R&D efficiency driven by AI-powered workflows.

A Resilient Global Operating Network: Automation, Worldwide Operations, ESG
GenScript continued to reinforce its global operating network to support long-term, high-quality growth. In 2025, the Group advanced its manufacturing footprint across NA, EU, and APAC, with increasing use of automation and digitalization to improve productivity, speed, and reliability. GenScript’s global operating model is designed to support stronger service consistency, greater supply resilience, and scalable execution across its businesses.

ESG Leadership and Responsible Growth
GenScript strengthened its ESG profile, being recognized by leading external benchmarks:

• MSCI ESG Rating upgraded to AA
• Included in the FTSE4Good Index Series
• Awarded EcoVadis Silver Medal
• Included in the S&P Sustainability Yearbook

These recognitions reflect GenScript’s ongoing commitment to responsible growth, operational integrity, and long-term stakeholder value-creation.

Outlook

Looking ahead to 2026, GenScript expects continued growth supported by rising demand for integrated biotechnology platforms, advanced therapeutics development, and higher productivity from automation and digitalized operations.

The Group’s business focus remains on:

• strengthening cross-platform synergy
• broadening global customer reach
• improving leverage through automation and digitalization
• advancing proprietary technologies across biologics and industrial biotechnology

Based on current trends and management guidance, GenScript expects:

• 15%–18% revenue growth for GenScript LSG
• 20%–25% fee-for-service revenue growth for ProBio
• 10%–15% revenue growth for Bestzyme

About GenScript Biotech Corporation

Founded in 2002 in New Jersey, GenScript Biotech Corporation operates through three core businesses; GenScript Life Science Group, ProBio, and Bestzyme. The Group accelerates innovation in biotech & healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to ‘Make People and Nature Healthier Through Biotechnology’, GenScript supports customers across the full innovation lifecycle (biotechnology research, drug discovery, biologics development, and industrial biotechnology applications) with a team of 5,700+ employees serving 200,000+ customers across 100+ countries.

Investor & Media Contacts

Investor Relations: ir@genscript.com
Media Inquiries: melis.inceer@genscript.com
Company Website: https://www.genscript.com

*To better reflect the key performance of the Group’s current operations, adjusted net profit is calculated by excluding the impact of the following items:
(i) share-based compensation expenses;
(ii) the impact of acquisitions and fair value losses on preferred shares;
(iii) losses from foreign exchange forward and option contracts;
(iv) impairment losses on long-term assets;
(v) foreign exchange gains or losses;
(vi) fair value gains or losses on non-current financial assets;
(vii) unrealized financing costs related to equity financing activities;
(viii) share of losses from Legend Biotech and service fees related to deconsolidation; and
(ix) impairment of investments in Legend Biotech.

This document is intended to provide a summary overview and does not constitute a complete description of the Company, its securities, or related matters. For more detailed information, please refer to the official announcement released by GenScript Group on March 15 on the Company’s website. All information is subject to the official announcement.

BEIJING, March 16, 2026 /PRNewswire/ — Bairong Inc. (HKEX:6608), a leading pioneer in enterprise AI agent solutions, announced that it will report 2025 annual results and hold online earnings presentation at 9:00 A.M. Beijing time on Friday, March 27, 2025. The presentation will be in Mandarin, while English interpretation will be provided for online participants.

Access 1: Webcast
Chinese and English Meeting link:
https://www.roadshowchina.cn/w/meet/rAxmQp 

Access 2: Phone Dial-in
Listeners may access the call by dialing the following numbers:

International: +86-23-62737100
Mainland China: 023-62737123/4008-063-263
HK China: +852-30183602/+800-961505

English Dial-in Password: 595868414
Chinese Dial-in Password:291375421

Please scan the QR code in the poster to register for the conference: 

SINGAPORE, March 16, 2026 /PRNewswire/ — Rao Family Foundation, a Singapore-based grantmaking foundation partnering with changemakers to solve social challenges, and Pro Bono SG (PBSG), a registered charity dedicated to enabling access to justice for Singapore’s marginalised communities, have signed a Memorandum of Understanding (MOU) today to launch the Inclusive Justice Law Centre, Singapore’s first dedicated legal centre for individuals with non-visible conditions.

The Inclusive Justice Law Centre will serve as a one-stop hub offering legal awareness, guidance, and representation to individuals with non-visible conditions and their caregivers — a population that has historically lacked dedicated legal support in Singapore.

The Rao Family Foundation will commit to funding more than $700,000 over two years to cover manpower costs, a Legal Support Fund, as well as training and workshops by the PBSG Training Academy. Under this partnership, the Inclusive Justice Law Centre aims to provide holistic legal awareness, guidance, and representation tailored to individuals with non-visible conditions and their caregivers.

Mr James Zou, Director at the Rao Family Foundation, said, “The Rao Family Foundation believes that a truly just society cannot exist when significant segments of our community remain unseen. To us, inclusivity means being intersectional, all-encompassing, and exhaustive. We are proud to support Pro Bono SG’s deliberate commitment to creating equity through legal support, advocacy, and systemic reform through the set-up of the Inclusive Justice Law Centre. We are confident this initiative will help ensure that everyone, regardless of whether their condition is visible, has meaningful access to justice and opportunity.”

The MOU signing was witnessed by Guest of Honour Mr Eric Chua, Senior Parliamentary Secretary, Ministry of Law and the Ministry of Social and Family Development. SPS Mr Eric Chua is also the co-chair of the Inclusive Justice Taskforce. The agreement was signed by Mr Jimmy Budiarto Rao, Chairman of the Rao Family Foundation, and Mr Dinesh Dhillon, Chairman of PBSG.

A Natural Extension of Rao Family Foundation’s Advocacy

The launch of the Inclusive Justice Law Centre represents the Rao Family Foundation’s commitment to extending inclusion beyond awareness to encompass equitable access to justice and legal protection. It marks a significant milestone in strengthening Singapore’s legal and social support framework and highlights a collective commitment to protecting the rights and dignity of individuals with non-visible conditions and supporting the long-term security and well-being of the families who care for them.

Addressing a Critical Gap in Access to Justice

Recognising that individuals with non-visible conditions, as well as their caregivers often face barriers in accessing legal support, the partnership seeks to bridge this critical gap and empower these individuals to seek timely and appropriate legal support. 

The Inclusive Justice Law Centre will be anchored by a full-time Singapore-qualified community lawyer who will specialise in advising and providing legal assistance to individuals with non-visible conditions. To strengthen the pro bono ecosystem, the community lawyer will also train and expand the volunteer pool, equipping volunteers with specialised knowledge and skills to support this community.

The Inclusive Justice Law Centre will also host curated workshops, as well as seminars and webinars focused on legal literacy and protection, designed with a deep understanding of the unique challenges faced by individuals with non-visible conditions, such as decision-making, communication, and self-advocacy. These initiatives also aim to address caregivers’ concerns around future planning, financial security and caregiving responsibilities.

Beyond legal support, the partnership aims to better support individuals with non-visible conditions and their caregivers by driving strategic research to strengthen broader access-to-justice efforts with key stakeholders across the legal and social service sectors.

Mr Dinesh Dhillon, Chairman of Pro Bono SG, said, “In our work, we have seen that access to justice is not only about having legal rights – it is about being able to understand and navigate the system. The Inclusive Justice Law Centre reflects our commitment to ensuring that individuals with non-visible conditions are seen, heard and supported throughout the legal process. Beyond assisting individual cases, we aim to build dedicated expertise and strengthen partnerships across the legal, social service and philanthropic sectors. Over time, our goal is to help shape a system that is more responsive, so that justice becomes truly accessible in practice.”

SINGAPORE, March 16, 2026 /PRNewswire/ — The Ngee Ann Kongsi and the Singapore Institute of Technology (SIT) have marked the naming of The Ngee Ann Kongsi Library at the SIT Punggol campus, a testament to the Kongsi’s enduring commitment to advancing education and empowering future generations. The occasion was witnessed by Guest of Honour Mr Baey Yam Keng, Minister of State, Ministry of Culture, Community and Youth & Ministry of Transport and Mayor, North East District.

Reflecting SIT’s digital-first learning strategy, the library provides students with seamless access to an extensive collection of digital academic resources, empowering them with knowledge and tools at their fingertips to thrive in a rapidly evolving digital world.

Designed as a physical hub for learning and community building, the technology-enabled space brings together students, academic staff and industry partners to collaborate, exchange ideas and work on projects. Equipped with facilities such as a creative media studio and computers with specialised software to support coursework, research and interdisciplinary collaboration, the library will also host programmes and initiatives that foster creativity, innovation and applied learning.

In 2021, The Ngee Ann Kongsi committed S$25 million to SIT over 10 years, with annual tranches of $2.5 million. The gift supports the development of The Ngee Ann Kongsi Library and the establishment of The Ngee Ann Kongsi Emergence Fund, which expands opportunities for SIT students to take part in overseas exchange programmes, global internships, and other experiential learning initiatives that enrich their education beyond the classroom.

Ms Nerissa Lai, a Year 2 student in SIT’s Hospitality Business degree programme and a recipient of The Ngee Ann Kongsi Scholarship, said, “The Ngee Ann Kongsi Scholarship has enabled me to explore opportunities beyond formal coursework, including overseas exposure programmes, by helping to offset my expenses. Being recognised for my academic achievements has also given me greater confidence to pursue experiential learning opportunities and motivated me to give back to the community through volunteering. I often study at the library, especially during exam periods and project deadlines. My favourite spot is the stepped study area in the centre, which is designed to minimise distractions and helps me stay focused. The spacious, calming environment also makes it a comfortable place to study and collaborate with classmates.”

Mr Chia Chor Meng, President of The Ngee Ann Kongsi, said, “Since our founding in or around 1845, The Ngee Ann Kongsi has remained steadfast in our mission to serve the community. We firmly believe that education is one of the most powerful ways to empower individuals and uplift society. It is our hope that this gift will expand access to diverse learning opportunities for SIT students, inspiring them to pursue academic excellence and realise their fullest potential.”

Professor Chua Kee Chaing, President of SIT said, “We are grateful for the long-standing partnership of The Ngee Ann Kongsi, which reflects a shared commitment to advancing education and creating opportunities that will benefit generations of learners. As Singapore’s University for Industry, applied learning is central to how we prepare students for the real world, through close collaboration with industry and the community. Purposefully designed to support this approach, The Ngee Ann Kongsi Library fosters collaboration, discovery and growth.”

Over the past decade, The Ngee Ann Kongsi has supported SIT through the following key contributions:

• 2021: $25 million for The Ngee Ann Kongsi Library and The Ngee Ann Kongsi Emergence Fund
• Ongoing:
  • The Ngee Ann Kongsi Scholarship supports deserving undergraduate students who are enrolled in full-time degree programmes at SIT. Since the SIT-Ngee Ann Kongsi Scholarship started in 2017, 450 scholarships have been disbursed as of March 2026, alongside nine The Ngee Ann Kongsi Gold Medals awarded to outstanding graduates.

This ongoing contribution builds upon a legacy of meaningful collaboration between SIT and The Ngee Ann Kongsi, reflecting a shared commitment to broadening access to education, nurturing talent, and advancing learning and innovation for generations to come.

BELIZE CITY, Belize, March 16, 2026 /PRNewswire/ — RoboForex, a financial broker, has announced the launch of swap-free trading for all its clients. The new feature represents a distinctive innovation in the forex industry and introduces a fundamentally different approach to overnight trading costs.

RoboForex Launches Swap-Free Trading for All Clients

RoboForex offers a comprehensive swap-free model, completely removing overnight fees (swaps). Crucially, this is achieved without introducing hidden costs, such as increased commissions or wider spreads, which are common among other market providers. By opening a swap-free account, RoboForex clients can run their strategies without incurring additional charges for holding positions overnight.

Enhancing the trader experience

The introduction of this feature is designed to lower entry barriers and create a more predictable cost structure for traders. By removing overnight swaps, RoboForex simplifies trading conditions and reduces cost-related uncertainty, particularly for those holding positions over longer periods.

In volatile market environments, where traders already navigate price fluctuations and risk exposure, eliminating overnight charges helps minimise additional cost pressure and supports a more focused trading experience. This can be particularly relevant when traders hold positions for extended periods during prolonged market trends, waiting for more favourable exit conditions.

“Following a successful test launch last year in several Latin American countries and strong positive feedback from clients, we decided to scale swap-free trading across all our markets,” said Douglas Abreu, LATAM Operations Director at RoboForex. “This step reflects our broader focus on simplifying trading conditions and making costs more transparent and predictable, giving traders more flexibility in managing longer-term positions.”

Key highlights of the swap-free accounts:

• Total transparency: no additional commissions or mark-ups are added to the spread in exchange for swap-free status
• Available to all RoboForex clients: swap-free trading is accessible on newly created accounts
• Broad instrument coverage: zero swaps apply for the most popular instruments, including metals and currencies

Building a low-barrier trading environment

The launch of swap-free trading aligns with RoboForex’s broader strategy of reducing cost-related barriers for clients. In addition to swap-free accounts, the company offers free withdrawals, allowing clients to withdraw funds without a commission up to three times per month. RoboForex also offers 0% commission on deposits, ensuring clients are not charged for funding their accounts.

By combining swap-free trading with transparent and cost-efficient funding and withdrawal conditions, RoboForex continues to develop a trading environment focused on market accessibility, clarity, and reduced structural costs for traders.

About RoboForex

RoboForex is a company that provides brokerage services, offering traders in financial markets access to its proprietary trading terminals and industry-leading third-party platforms. RoboForex Ltd operates under brokerage license number FSC 9759600.

View more detailed information about the Company’s products and activities on the website roboforex.com.